(Q30500238)

18 October 2017

9 references

23 March 2019

3 April 2019

4 August 2019

27 September 2019

27 November 2019

13 December 2019

1 August 2020

14 September 2020

29 October 2020

1 reference

1 reference

Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis (English)

1 reference

murine-derived monoclonal antibodies

18 October 2017

9 references

23 March 2019

3 April 2019

4 August 2019

27 September 2019

27 November 2019

13 December 2019

1 August 2020

14 September 2020

29 October 2020

9 references

23 March 2019

3 April 2019

4 August 2019

27 September 2019

27 November 2019

13 December 2019

1 August 2020

14 September 2020

29 October 2020

1 reference

4 August 2019

1 reference

27 September 2019

1 reference

27 November 2019

1 reference

13 December 2019

1 reference

1 August 2020

1 reference

14 September 2020

1 reference

29 October 2020

1 reference

1 reference

1 reference

5

1 reference

18 October 2017

Simone Lanini

1

0 references

author name string

Aoife C Molloy

2

1 reference

18 October 2017

Paul E Fine

3

1 reference

18 October 2017

Archibald G Prentice

4

1 reference

18 October 2017

Christopher C Kibbler

6

1 reference

18 October 2017

language of work or name

English

0 references

publication date

12 April 2011

10 references

18 October 2017

23 March 2019

3 April 2019

4 August 2019

27 September 2019

27 November 2019

13 December 2019

1 August 2020

14 September 2020

29 October 2020

10 references

18 October 2017

23 March 2019

3 April 2019

4 August 2019

27 September 2019

27 November 2019

13 December 2019

1 August 2020

14 September 2020

29 October 2020

9

1 reference

18 October 2017

36

1 reference

Creative Commons Attribution 2.0 Generic

18 October 2017

9 references

23 March 2019

3 April 2019

4 August 2019

27 September 2019

27 November 2019

13 December 2019

1 August 2020

14 September 2020

on focus list of Wikimedia project

29 October 2020

copyright status

copyrighted

0 references

ScienceSource

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/1741-7015-9-36

0 references

cites work

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3094236

A systematic review and meta-analysis of rituximab-based immunochemotherapy for subtypes of diffuse large B cell lymphoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3094236

Rituximab-associated infections

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3094236

A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3094236

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3094236

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3094236

Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3094236

Classification of lymphoid neoplasms: the microscope as a tool for disease discovery

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3094236

Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3094236

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3094236

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3094236

Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3094236

Treatment of non-Hodgkin's lymphoma: a look over the past decade.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3094236

Fatal West Nile Virus infection after rituximab/fludarabine--induced remission for non-Hodgkin's lymphoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3094236

Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3094236

Grading quality of evidence and strength of recommendations

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3094236

Evidence-based use of colony-stimulating factors in elderly cancer patients

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3094236

Molecular evidence of persistent echovirus 13 meningoencephalitis in a patient with relapsed lymphoma after an outbreak of meningitis in 2000.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3094236

Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3094236

Generation of allocation sequences in randomised trials: chance, not choice

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3094236

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3094236

Bias in meta-analysis detected by a simple, graphical test

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3094236

Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project

20 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-36

Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-36

Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-36

Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-36

Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-36

Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-36

Pseudo-bowel obstruction due to varicella zoster virus infection after autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-36

Enteroviral meningoencephalitis in a patient with non-Hodgkin's lymphoma treated previously with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-36

Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-36

Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-36

Persistent and relapsing babesiosis in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-36

Increased incidence of interstitial pneumonia by CHOP combined with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-36

Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3094236

Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab

26 November 2018

1 reference

12 December 2020

Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder

1 reference

12 December 2020

Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody

1 reference

12 December 2020

Cytomegalovirus-associated meningoradiculoneuritis after treatment of mantle cell lymphoma with a combination of chemotherapy and rituximab

1 reference

12 December 2020

Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy

1 reference

12 December 2020

Identifiers

DOI

10.1186/1741-7015-9-36

1 reference

Dimensions Publication ID

18 October 2017

1028951594

0 references

Fatcat ID

release_tc2wkinavngttl4ohr2vjufksq

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tc2wkinavngttl4ohr2vjufksq

24 November 2022

mapped directly with Wikidata item

1 reference

18 October 2017

1 reference